Overview A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus Nephritis Status: Not yet recruiting Trial end date: 2025-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis. Phase: Phase 2 Details Lead Sponsor: RemeGen Co., Ltd.